Butterfly Network, Inc. (BFLY) is a Healthcare stock trading at $9.16 (as of 2026-08-20), with a market capitalization of $2.40B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Butterfly Network, Inc., a digital health company, develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+, a point-of-care ultrasound imaging device that connects with a smartphone, tablet, and hospital computer system; and Butterfly Blueprint, a system-wide ultrasound platform with Compass software that integrates into a healthcare system's clinical and administrative infrastructure. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions, to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as clinical support and services. Butterfly Network, Inc. was incorporated in 2011 and is headquartered in Guilford, Connecticut.
Butterfly Network develops and commercializes ultrasound imaging systems, including handheld whole-body ultrasound (Butterfly iQ and iQ+), and system-wide platforms (Butterfly Blueprint), and it monetizes through product sales plus software and other services, including embedded and subscription revenue connected to the healthcare workflow.
The profit model combines upfront ultrasound system and product sales (hardware) with ongoing monetization through embedded, subscription, and software and other services revenue tied to continued clinical use.
Business quality (Weak): The company is built around ultrasound systems plus recurring software and subscription-style monetization, but the latest-quarter operating result remains deeply loss-making (operating margin -52.3%), so execution on recurring revenue and unit traction is crucial to watch.
| Price | $9.16 |
| Market Cap | $2.40B |
| Price / Book | 12.68 |
| Price / Sales | 21.41 |
| FCF Yield | -1.8% |
| Revenue (TTM) | $97.61M |
| Net Margin | -79.0% |
| Revenue Growth (YoY) | 39.5% |
| EPS Growth (YoY) | -16.7% |
| FCF Growth (YoY) | 113.9% |
| Altman Z-Score | 9.47 (safe) |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Medical Equipment) | 32.9 |
| Top Institutional Holder | BlackRock, Inc. ($64.48M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Medical Equipment |
| CEO | Joseph DeVivo |
| Employees | 190 |
| Country | US |
| IPO Date | 2020-07-13 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.